{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:38:52Z","timestamp":1792478332904,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10571-8","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:48:09Z","timestamp":1782748089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics reveals tumor microenvironment heterogeneity and therapeutic vulnerabilities in peritoneal metastasis of gastric cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Wen","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1527-6400","authenticated-orcid":false,"given":"Xujin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8599-5306","authenticated-orcid":false,"given":"Kunzhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8322-4197","authenticated-orcid":false,"given":"Huiqin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-153X","authenticated-orcid":false,"given":"Wangyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"10571_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74, 229\u2013263 (2024).","journal-title":"CA Cancer J Clin"},{"key":"10571_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","volume":"24","author":"WJ Koemans","year":"2021","unstructured":"Koemans, W. J. et al. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer 24, 800\u2013809 (2021).","journal-title":"Gastric Cancer"},{"key":"10571_CR3","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.21.02745","volume":"40","author":"YX Gwee","year":"2022","unstructured":"Gwee, Y. X. et al. Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis. J Clin Oncol 40, 2830 (2022).","journal-title":"J Clin Oncol"},{"key":"10571_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamasurg.2022.0182","volume":"157","author":"GZ Li","year":"2022","unstructured":"Li, G. Z., Doherty, G. M. & Wang, J. Surgical management of gastric cancer: a review. JAMA Surg 157, 446\u2013454 (2022).","journal-title":"JAMA Surg"},{"key":"10571_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36310-9","volume":"14","author":"XZ Huang","year":"2023","unstructured":"Huang, X. Z. et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat Commun 14, 822 (2023).","journal-title":"Nat Commun"},{"key":"10571_CR6","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41590-024-01960-4","volume":"25","author":"NM Haynes","year":"2024","unstructured":"Haynes, N. M., Chadwick, T. B. & Parker, B. S. The complexity of immune evasion mechanisms throughout the metastatic cascade. Nat Immunol 25, 1793\u20131808 (2024).","journal-title":"Nat Immunol"},{"key":"10571_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"10571_CR8","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar, V. et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov 12, 670\u2013691 (2022).","journal-title":"Cancer Discov"},{"key":"10571_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-020-1125-8","volume":"27","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 27, 141\u2013151 (2021).","journal-title":"Nat Med"},{"key":"10571_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong, X. et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol 17, 65 (2024).","journal-title":"J Hematol Oncol"},{"key":"10571_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02092-x","volume":"23","author":"S Cousin","year":"2024","unstructured":"Cousin, S. et al. Identification of microenvironment features associated with primary resistance to anti-PD-1\/PD-L1+antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics. Mol Cancer 23, 197 (2024).","journal-title":"Mol Cancer"},{"key":"10571_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S2468-1253(24)00043-8","volume":"9","author":"R Sundar","year":"2024","unstructured":"Sundar, R. & Smyth, E. C. Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer. Lancet Gastroenterol Hepatol 9, 495\u2013497 (2024).","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10571_CR13","doi-asserted-by":"crossref","unstructured":"Chiang, E. Y. & Mellman, I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J. Immunother. Cancer 10, e004711 (2022).","DOI":"10.1136\/jitc-2022-004711"},{"key":"10571_CR14","doi-asserted-by":"crossref","unstructured":"Sun, Y. et al. Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology 81, 791\u2013807 (2024).","DOI":"10.1097\/HEP.0000000000000934"},{"key":"10571_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2023.12.008","volume":"42","author":"J Wienke","year":"2024","unstructured":"Wienke, J. et al. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer Cell 42, 283\u2013300.e288 (2024).","journal-title":"Cancer Cell"},{"key":"10571_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 23, 781\u2013792 (2022).","journal-title":"Lancet Oncol"},{"key":"10571_CR17","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2023.41.16_suppl.4010","volume":"41","author":"RS Finn","year":"2023","unstructured":"Finn, R. S. et al. Results from the MORPHEUS-liver study: Phase Ib\/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). Journal of Clinical Oncology 41, 4010\u20134010 (2023).","journal-title":"Journal of Clinical Oncology"},{"key":"10571_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 21, 354\u2013369 (2024).","journal-title":"Nat Rev Clin Oncol"},{"key":"10571_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","volume":"10","author":"P Singh","year":"2017","unstructured":"Singh, P., Toom, S. & Huang, Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 10, 105 (2017).","journal-title":"J Hematol Oncol"},{"key":"10571_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 29, 2133\u20132141 (2023).","journal-title":"Nat Med"},{"key":"10571_CR21","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"10571_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.730","volume":"12","author":"H Jiang","year":"2022","unstructured":"Jiang, H. et al. Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing. Clin Transl Med. 12, e730 (2022).","journal-title":"Clin Transl Med"},{"key":"10571_CR23","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/cdd.2014.228","volume":"22","author":"YW Moon","year":"2015","unstructured":"Moon, Y. W. et al. LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death Differ 22, 1341\u20131352 (2015).","journal-title":"Cell Death Differ"},{"key":"10571_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06594-w","volume":"15","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. TGF-\u03b2-driven LIF expression influences neutrophil extracellular traps (NETs) and contributes to peritoneal metastasis in gastric cancer. Cell Death Dis 15, 218 (2024).","journal-title":"Cell Death Dis"},{"key":"10571_CR25","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. FOXP4 is a Direct YAP1 Target that Promotes Gastric Cancer Stemness and Drives Metastasis. Cancer Res. 84, 3574\u20133588 (2024).","DOI":"10.1158\/0008-5472.CAN-23-3074"},{"key":"10571_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey, A., Varelas, X. & Guan, K. L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 19, 480\u2013494 (2020).","journal-title":"Nat Rev Drug Discov"},{"key":"10571_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110638","volume":"27","author":"Q Shi","year":"2024","unstructured":"Shi, Q. et al. GRP94 promotes anoikis resistance and peritoneal metastasis through YAP\/TEAD1 pathway in gastric cancer. iScience 27, 110638 (2024).","journal-title":"iScience"},{"key":"10571_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu, G. et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med. 5, 101710 (2024).","journal-title":"Cell Rep Med"},{"key":"10571_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","volume":"9","author":"N Yin","year":"2024","unstructured":"Yin, N. et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct Target Ther 9, 126 (2024).","journal-title":"Signal Transduct Target Ther"},{"key":"10571_CR30","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cell.2024.03.011","volume":"187","author":"T Cao","year":"2024","unstructured":"Cao, T. et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8(+) T cells. Cell 187, 2288\u20132304.e2227 (2024).","journal-title":"Cell"},{"key":"10571_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112437","volume":"42","author":"Q Luo","year":"2023","unstructured":"Luo, Q. et al. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep 42, 112437 (2023).","journal-title":"Cell Rep"},{"key":"10571_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral, D. et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7, 91 (2021).","journal-title":"Nat Rev Dis Primers"},{"key":"10571_CR33","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037.e1014 (2018).","journal-title":"Cell"},{"key":"10571_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/gutjnl-2022-328408","volume":"73","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. NNMT enriches for AQP5(+) cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma. Gut 73, 63\u201377 (2023).","journal-title":"Gut"},{"key":"10571_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13046-021-02003-8","volume":"40","author":"S Song","year":"2021","unstructured":"Song, S. et al. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res. 40, 207 (2021).","journal-title":"J Exp Clin Cancer Res"},{"key":"10571_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01877-w","volume":"22","author":"Z Zeng","year":"2023","unstructured":"Zeng, Z. et al. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer 22, 172 (2023).","journal-title":"Mol Cancer"},{"key":"10571_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215914","volume":"15","author":"S Bootsma","year":"2023","unstructured":"Bootsma, S., Bijlsma, M. F. & Vermeulen, L. The molecular biology of peritoneal metastatic disease. EMBO Mol. Med. 15, e15914 (2023).","journal-title":"EMBO Mol. Med"},{"key":"10571_CR38","first-page":"809","volume":"18","author":"T Kawamura","year":"2001","unstructured":"Kawamura, T. et al. Significance of integrin alpha2\/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int J Oncol 18, 809\u2013815 (2001).","journal-title":"Int J Oncol"},{"key":"10571_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1756-9966-29-139","volume":"29","author":"ZD Lv","year":"2010","unstructured":"Lv, Z. D. et al. Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis. J Exp Clin Cancer Res. 29, 139 (2010).","journal-title":"J Exp Clin Cancer Res"},{"key":"10571_CR40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10120-013-0302-6","volume":"17","author":"K Sentani","year":"2014","unstructured":"Sentani, K. et al. Clinicopathological significance of MMP-7, laminin \u03b32 and EGFR expression at the invasive front of gastric carcinoma. Gastric Cancer 17, 412\u2013422 (2014).","journal-title":"Gastric Cancer"},{"key":"10571_CR41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s43018-021-00240-6","volume":"2","author":"Y Tanaka","year":"2021","unstructured":"Tanaka, Y. et al. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer 2, 962\u2013977 (2021).","journal-title":"Nat Cancer"},{"key":"10571_CR42","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin Cancer Res"},{"key":"10571_CR43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda, T. & Wang, Y. A. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer 10, 627\u2013642 (2024).","journal-title":"Trends Cancer"},{"key":"10571_CR44","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2023.06.005","volume":"41","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell 41, 1407\u20131426.e1409 (2023).","journal-title":"Cancer Cell"},{"key":"10571_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","volume":"40","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell 40, 424\u2013437.e425 (2022).","journal-title":"Cancer Cell"},{"key":"10571_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41421-022-00445-8","volume":"8","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma. Cell Discov 8, 101 (2022).","journal-title":"Cell Discov"},{"key":"10571_CR47","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor, W. A. et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39, 1342\u20131360.e1314 (2021).","journal-title":"Cancer Cell"},{"key":"10571_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55424-2","volume":"16","author":"S Sivakumar","year":"2025","unstructured":"Sivakumar, S. et al. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nat Commun 16, 1397 (2025).","journal-title":"Nat Commun"},{"key":"10571_CR49","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Interactions between LAMP3+ dendritic cells and T-cell subpopulations promote immune evasion in papillary thyroid carcinoma. J. Immunother. Cancer 12, e008983 (2024).","DOI":"10.1136\/jitc-2024-008983"},{"key":"10571_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou, Y. et al. The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer. Adv Sci (Weinh) 10, e2203699 (2023).","journal-title":"Adv Sci (Weinh)"},{"key":"10571_CR51","doi-asserted-by":"crossref","unstructured":"Xing. X. et al. Pan-cancer human brain metastases atlas at single-cell resolution. Cancer Cell 43, 1242\u20131260.e9 (2025).","DOI":"10.1016\/j.ccell.2025.03.025"},{"key":"10571_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.immuni.2022.12.010","volume":"56","author":"D Briukhovetska","year":"2023","unstructured":"Briukhovetska, D. et al. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity 56, 143\u2013161.e111 (2023).","journal-title":"Immunity"},{"key":"10571_CR53","doi-asserted-by":"publisher","first-page":"e28328","DOI":"10.4161\/onci.28328","volume":"3","author":"P Renner","year":"2014","unstructured":"Renner, P. et al. KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance. Oncoimmunology 3, e28328 (2014).","journal-title":"Oncoimmunology"},{"key":"10571_CR54","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ccell.2024.05.004","volume":"42","author":"CS McGinnis","year":"2024","unstructured":"McGinnis, C. S. et al. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell 42, 1018\u20131031.e1016 (2024).","journal-title":"Cancer Cell"},{"key":"10571_CR55","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","volume":"25","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet, L. et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol 25, 1474\u20131488 (2024).","journal-title":"Nat Immunol"},{"key":"10571_CR56","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u20134251.e4220 (2023).","journal-title":"Cell"},{"key":"10571_CR57","doi-asserted-by":"crossref","unstructured":"de Andrade, L. F. et al. Discovery of specialized NK cell populations infiltrating human melanoma metastases. JCI Insight 4, e133103 (2019).","DOI":"10.1172\/jci.insight.133103"},{"key":"10571_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19, 723\u2013732 (2018).","journal-title":"Nat Immunol"},{"key":"10571_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"10571_CR60","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","volume":"147","author":"M Cordenonsi","year":"2011","unstructured":"Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759\u2013772 (2011).","journal-title":"Cell"},{"key":"10571_CR61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41416-025-03046-w","volume":"133","author":"H Yu","year":"2025","unstructured":"Yu, H., Jin, S., Zeng, M., Yang, Z. & Wang, X. TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory. Br J Cancer 133, 743\u2013755 (2025).","journal-title":"Br J Cancer"},{"key":"10571_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08203-w","volume":"16","author":"Y Xia","year":"2025","unstructured":"Xia, Y. et al. Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy. Cell Death Dis 16, 890 (2025).","journal-title":"Cell Death Dis"},{"key":"10571_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202412800","volume":"21","author":"W Wang","year":"2025","unstructured":"Wang, W. et al. Whole-Component Antigen Nanovaccines Combined With aTIGIT for Enhanced Innate and Adaptive Anti-tumor Immunity. Small 21, e2412800 (2025).","journal-title":"Small"},{"key":"10571_CR64","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature 627, 646\u2013655 (2024).","journal-title":"Nature"},{"key":"10571_CR65","doi-asserted-by":"crossref","unstructured":"Gaspar, M. et al. An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. J. Immunother. Cancer 13, e011857 (2025).","DOI":"10.1136\/jitc-2025-011857"},{"key":"10571_CR66","doi-asserted-by":"crossref","unstructured":"Gao, J. et al. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J. Immunother. Cancer 11, e006704 (2023).","DOI":"10.1136\/jitc-2023-006704"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10571-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10571-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:43:55Z","timestamp":1792475035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10571-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10571"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10571-8","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1371"}}